Skip to main content
Search
Main content
bioRxiv : the preprint server for biology
Published

Generation of <em>C9orf72</em> repeat knock-in iPSC lines for modelling ALS and FTD

Authors

Rachel Coneys, Alexander J Cammack, Remya R Nair, David Thompson, Jonas Mechtersheimer, Mireia Carcolé, Yashica Gupta, Gabriel E Rech, Michael Flower, Niamh O'Brien, Marc-David Ruepp, Sarah Mizielinska, Fiona Ducotterd, Sarah J Tabrizi, Elizabeth M C Fisher, Thomas J Cunningham, Michael Ward, William C Skarnes, Adrian M Isaacs

Abstract

bioRxiv [Preprint]. 2025 Feb 11:2025.02.10.637041. doi: 10.1101/2025.02.10.637041.

ABSTRACT

Induced pluripotent stem cell (iPSC) models are powerful tools for neurodegenerative disease modelling, as they allow mechanistic studies in a human genetic environment and they can be differentiated into a range of neuronal and non-neuronal cells. However, these models come with inherent challenges due to line-to-line and clonal variability. To combat this issue, the iPSC Neurodegenerative Disease Initiative (iNDI) has generated an iPSC repository using a single clonal reference line, KOLF2.1J, into which disease-causing mutations and revertants are introduced via gene editing. Here we describe the generation and validation of lines carrying the most common causative mutation for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a repeat expansion in the C9orf72 gene, for the iNDI collection of neurodegenerative iPSC models. We demonstrate that these C9orf72 knock-in lines differentiate efficiently into neurons and display characteristic C9orf72-associated pathologies, including reduced C9orf72 levels and the presence of dipeptide repeat proteins (DPRs) and RNA foci, which increase in abundance over time in culture. These pathologies are not present in revertant cells lacking the repeat expansion. These repeat expansion and revertant cell lines are now available to academic and for-profit institutions through the JAX iPS cell repository and will help to facilitate and standardise iPSC-based ALS/FTD research.

PMID:41030957 | PMC:PMC12478360 | DOI:10.1101/2025.02.10.637041

UK DRI Authors

Image of Marc-David Ruepp

Prof Marc-David Ruepp

Group Leader

Exploring RNA metabolism in health and neurodegeneration

Prof Marc-David Ruepp
Sarah Mizielinska profile

Dr Sarah Mizielinska

Group Leader

Understanding the precise mechanisms of nucleocytoplasmic dysfunction in FTD and ALS

Dr Sarah Mizielinska
Fiona Ducotterd, smiling female with dark brown hair

Prof Fiona Ducotterd

UK DRI Affiliate Member

Chief Scientific Officer of the Alzheimer's Research UK UCL Drug Discovery Institute

Prof Fiona Ducotterd